Seelos Therapeutics Announces Amendment of SLS-002 Agreement to Repurchase a Significant Portion of Royalties for SLS-002 (Intranasal Racemic Ketamine Program) prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Seelos Therapeutics to Participate in the 33rd Annual Roth Conference
Seelos Therapeutics, Inc. a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced that it will participate in the 33 rd Annual Roth Conference which will be held virtually on March 15-17, 2021 . Raj Mehra, Ph.D., Chairman and CEO, will host 1×1 meetings via conference calls on March 16 th and 17 th . About Seelos …
Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced that it will participate in the 33 rd Annual Roth Conference which will be held virtually on March 15-17, 2021 .
Seelos Therapeutics, Inc. a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced that it will participate in Canaccord Genuity’s New Paradigms and Treatment Approaches in Mental Health virtual conference, Wednesday, February 3 rd and Thursday, February 4 th 2021. Raj Mehra, Ph.D., Chairman and CEO, will present on …
Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced that it will participate in Canaccord Genuity’s New Paradigms and Treatment Approaches in Mental Health virtual conference, Wednesday, February 3 rd and Thursday, February 4 th 2021.
Seelos Therapeutics, Inc. a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, announced today that it has been granted a patent from the Australian Patent Office covering SLS-005 titled: “Treatment of Protein Aggregation Myopathic and Neurodegenerative Diseases by Parenteral Administration of Trehalose”. The issued patent covers a …
– Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, announced today that it has been granted a patent from the Australian Patent Office (Australian patent number 2019204513) covering SLS-005 titled: “Treatment of Protein Aggregation Myopathic and Neurodegenerative Diseases by Parenteral Administration of Trehalose”.
Share this article
Share this article
NEW YORK, Jan. 29, 2021 /PRNewswire/ Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, announced today that it has been granted a patent from the Australian Patent Office (Australian patent number 2019204513) covering SLS-005 titled: Treatment of Protein Aggregation Myopathic and Neurodegenerative Diseases by Parenteral Administration of Trehalose .
The issued patent covers a method for treating a disease associated with abnormal protein aggregation and/or inclusion body formation in myocytes, neurons, extracellular compartments, or alleviating at least one symptom associated therewith, in a human subject in need thereof comprised of an intravenous administration of a therapeutically effective amount of a pharmaceutical formulation, with trehalose as the sole active ingredient, that complies with other paramet